Literature DB >> 14742668

Lessons from the CYP3A4 promoter.

Erin G Schuetz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14742668     DOI： 10.1124/mol.65.2.279

Source DB:  PubMed          Journal:  Mol Pharmacol        ISSN： 0026-895X            Impact factor:   4.436


× No keyword cloud information.
  12 in total

Review 1.  The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions.

Authors:  Abdo Haddad; Mellar Davis; Ruth Lagman
Journal:  Support Care Cancer       Date:  2006-12-01       Impact factor: 3.603

2.  Altered cytochrome 2E1 and 3A P450-dependent drug metabolism in advanced ovarian cancer correlates to tumour-associated inflammation.

Authors:  Sebastian Trousil; Patrizia Lee; Robert J Edwards; Lynn Maslen; Jingky P Lozan-Kuehne; Ramya Ramaswami; Eric O Aboagye; Stephen Clarke; Christopher Liddle; Rohini Sharma
Journal:  Br J Pharmacol       Date:  2019-08-05       Impact factor: 8.739

3.  Role of Chromatin Structural Changes in Regulating Human CYP3A Ontogeny.

Authors:  Nicholas L Giebel; Jeffrey D Shadley; D Gail McCarver; Kenneth Dorko; Roberto Gramignoli; Stephen C Strom; Ke Yan; Pippa M Simpson; Ronald N Hines
Journal:  Drug Metab Dispos       Date:  2016-02-26       Impact factor: 3.922

4.  High frequency and founder effect of the CYP3A4*20 loss-of-function allele in the Spanish population classifies CYP3A4 as a polymorphic enzyme.

Authors:  M Apellániz-Ruiz; L Inglada-Pérez; M E G Naranjo; L Sánchez; V Mancikova; M Currás-Freixes; A A de Cubas; I Comino-Méndez; S Triki; A Rebai; M Rasool; G Moya; M Grazina; G Opocher; A Cascón; P Taboada-Echalar; M Ingelman-Sundberg; A Carracedo; M Robledo; A Llerena; C Rodríguez-Antona
Journal:  Pharmacogenomics J       Date:  2014-11-04       Impact factor: 3.550

Review 5.  Copy number variation in the domestic dog.

Authors:  Carlos E Alvarez; Joshua M Akey
Journal:  Mamm Genome       Date:  2011-12-04       Impact factor: 2.957

6.  Gene-specific effects of inflammatory cytokines on cytochrome P450 2C, 2B6 and 3A4 mRNA levels in human hepatocytes.

Authors:  Alison E Aitken; Edward T Morgan
Journal:  Drug Metab Dispos       Date:  2007-06-18       Impact factor: 3.922

7.  Characterization of human cytochrome P450 enzymes catalyzing domperidone N-dealkylation and hydroxylation in vitro.

Authors:  Bryan A Ward; Alan Morocho; Abdullah Kandil; Raymond E Galinsky; David A Flockhart; Zeruesenay Desta
Journal:  Br J Clin Pharmacol       Date:  2004-09       Impact factor: 4.335

8.  Genetic predictors of interindividual variability in hepatic CYP3A4 expression.

Authors:  Vishal Lamba; John C Panetta; Stephen Strom; Erin G Schuetz
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

9.  Genetic variation in aldo-keto reductase 1D1 (AKR1D1) affects the expression and activity of multiple cytochrome P450s.

Authors:  Amarjit S Chaudhry; Ranjit K Thirumaran; Kazuto Yasuda; Xia Yang; Yiping Fan; Stephen C Strom; Erin G Schuetz
Journal:  Drug Metab Dispos       Date:  2013-05-23       Impact factor: 3.922

10.  The genomic architecture of segmental duplications and associated copy number variants in dogs.

Authors:  Thomas J Nicholas; Ze Cheng; Mario Ventura; Katrina Mealey; Evan E Eichler; Joshua M Akey
Journal:  Genome Res       Date:  2009-01-07       Impact factor: 9.043
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.